Human Papillomavirus (HPV) Infection Vaccines Market Regional Analysis

Large number of clinical trials conducted by pharmaceutical and biopharmaceutical companies are expected to fuel growth of the HPV infection vaccine market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Currently studies are in phase I clinical trial. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Moreover, increasing research on therapeutic vaccine for treatment of HPV infection to address unmet medical need is expected to boost growth of the human papilloma virus (HPV) infection vaccines market. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated phase 3 in June 2017.

Governmental and non-governmental organization plays important role in increasing awareness through immunization program, in turn driving growth of the human papillomavirus infection vaccine market. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Programme was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Get The Holistic SAMPLE Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1588

Furthermore, global HPV-related disease burden is expected to drive growth of the human papillomavirus (HPV) infection vaccines market. According to National Cancer Institute, 2015, HPV type 16 and type 18, causes around 70% of cervical cancer and is responsible for almost all cervical cancer. According to American Society of Clinical Oncology (ASCO), in 2017, an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4,210 deaths every year. According to World Health Organization (WHO), 2014, HPV type 6 and type 11 are responsible for 90% of the anogenital warts.

Human Papillomavirus (HPV) Infection Vaccines Market Restrains

The human papillomavirus infection vaccine market is expected to constrain by limited number of Food and Drug Administrations (FDA) approved commercial vaccines. High cost of vaccine development is also expected to hinder the human papillomavirus (HPV) infection vaccines market growth over the forecast period. Moreover, variable immunization coverage is estimated to impact the regional size. For instance, economies such as U.K and Mexico has 80% vaccination coverage whereas full-dosage coverage remains below 50% in France and in the U.S.

Regional segmentation of human papillomavirus (HPV) infection vaccine market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America comprises major share of the human papillomavirus infection treatment vaccine market, owing to high prevalence of cervical cancer, local market players and increasing governmental initiatives, followed by Europe. For instance, according to WHO 2016, currently 86% of America and 62% of European region girls have access to free HPV vaccination. Moreover, incidence of cervical cancer in Europe was 58,348 individuals per million in 2012. However, Asia Pacific is expected to witness significant growth during forecast period, due to awareness among the population for immunization.

Download The PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1588

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website:https://www.coherentwire.com

This release was published on openPR.